Thymoglobulin Induction in Kidney Transplant Recipients
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline)
administration in the kidney transplant recipient is able to reduce the amount of damage that
kidneys transplanted from deceased donors sustains on reperfusion.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborators:
Genzyme, a Sanofi Company Oxford University Hospitals NHS Trust